Aberdeen Group
CRBU icon

Aberdeen Group’s Caribou Biosciences CRBU Stock Holding History

Aberdeen Group’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,212,541
Closed -$2.3M – 946
2026
Q1 		$2.3M Sell
1,212,541
-176,364
-13% -$303K ﹤0.01% 759
2025
Q4 		$2.21M Hold
1,388,905
– – ﹤0.01% 770
2025
Q3 		$3.24M Buy
1,388,905
+491,326
+55% +$928K 0.01% 738
2025
Q2 		$1.13M Buy
897,579
+486,435
+118% +$478K ﹤0.01% 822
2025
Q1 		$375K Buy
411,144
+229,657
+127% +$298K ﹤0.01% 889
2024
Q4 		$289K Hold
181,487
– – ﹤0.01% 898
2024
Q3 		$356K Hold
181,487
– – ﹤0.01% 863
2024
Q2 		$298K Hold
181,487
– – ﹤0.01% 895
2024
Q1 		$933K Hold
181,487
– – ﹤0.01% 828
2023
Q4 		$1.04M Buy
+181,487
New +$897K ﹤0.01% 831

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Aberdeen Group's CRBU Position: Q2 2026 in Review

Aberdeen Group sold out of Caribou Biosciences (CRBU) in Q2 2026, closing a stake of 1,212,541 shares — an estimated $2.3M sold.

Aberdeen Group first reported a position in CRBU in Q4 2023 and held it in 10 quarters. The position peaked at $3.24M in Q3 2025. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Aberdeen Group reported no remaining Caribou Biosciences position as of Q2 2026 after selling out during the quarter.
  • Aberdeen Group sold 1,212,541 Caribou Biosciences shares in Q2 2026, an estimated $2.3M.
  • Aberdeen Group first reported a position in Caribou Biosciences in Q4 2023 and held it in 10 quarters.
  • Aberdeen Group's Caribou Biosciences position peaked at $3.24M in Q3 2025.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.